Role of p53 in the ability of 1,2-diaminocyclohexane-diacetato-dichloro-Pt(IV) to circumvent cisplatin resistance

被引:22
作者
Siddik, ZH [1 ]
Hagopian, GS [1 ]
Thai, G [1 ]
Tomisaki, S [1 ]
Toyomasu, T [1 ]
Khokhar, AR [1 ]
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA
关键词
cisplatin; drug resistance; p53; toxicity;
D O I
10.1016/S0162-0134(99)00144-0
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Several reports indicate that the mechanism of resistance to cisplatin is multifactorial. However, DNA damage tolerance appears to be the more significant mechanism. It is clear that resistance in general is a major clinical concern, and a number of approaches have been taken to circumvent this clinical impediment. One approach is through analog development, and we have identified 1,2-diaminocyclohexane-diacetatodichloro-platinum(IV) as an analog with activity in cisplatin resistance. The activity is greatest against ovarian tumor cell lines where the latent, non-inducible wild-type p53 function can be reactivated by the analog. This functional activation of p53 also corresponds to a reduced threshold for tolerance to DNA damage induced by the analog. Interestingly, cell lines with mutant or null p53 are cross-resistant to the analog. The data indicate that cisplatin resistance due to an increase in DNA damage tolerance can arise through a loss of p53 function, and that functional activation of latent wild-type p53 by the analog facilitates cell death and circumvents this resistance mechanism. (C)1999 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:65 / 70
页数:6
相关论文
共 48 条
[1]  
Ahnen DJ, 1998, CANCER RES, V58, P1149
[2]  
ANDREWS PA, 1990, CANCER CELL-MON REV, V2, P35
[3]  
BEHRENS BC, 1987, CANCER RES, V47, P414
[4]  
BLATTER EE, 1984, BIOCHEMISTRY-US, V23, P4817, DOI 10.1021/bi00316a001
[5]  
BORCH RF, 1988, PLATINUM OTHER METAL, P207
[6]  
BURCHENAL JH, 1979, CANCER TREAT REP, V63, P1493
[7]   PHASE-I STUDIES WITH CARBOPLATIN AT THE ROYAL-MARSDEN-HOSPITAL [J].
CALVERT, AH ;
HARLAND, SJ ;
NEWELL, DR ;
SIDDIK, ZH ;
HARRAP, KR .
CANCER TREATMENT REVIEWS, 1985, 12 :51-57
[8]  
CHANEY SG, 1990, CANCER RES, V50, P4539
[9]  
DURANT JR, 1980, CISPLATIN CURRENT ST, P317
[10]   GLUTATHIONE-MEDIATED ACTIVATION OF ANTICANCER PLATINUM(IV) COMPLEXES [J].
EASTMAN, A .
BIOCHEMICAL PHARMACOLOGY, 1987, 36 (23) :4177-4178